Literature DB >> 24304429

A retrospective analysis of the risk factors for allergic reactions induced by the administration of oxaliplatin.

H Yamauchi1, T Goto, K Takayoshi, K Sagara, M Uoi, C Kawanabe, M Matsunaga, T Miyoshi, K Uchino, N Misumi, T Nishino.   

Abstract

This study retrospectively investigated the clinical features and risk factors of allergic reactions induced by oxaliplatin administration. This study investigated the incidence of allergic reactions and analysed the background and laboratory data in patients with colorectal cancer treated with oxaliplatin-based chemotherapy at Kyushu Medical Center between April 2012 and September 2012. A total of 62 patients were included in this study. The number of patients in the allergic and non-allergic groups was 7 and 55 respectively. The incidence of allergic reactions was 11.3%. We compared the patients' characteristics and laboratory data between the two groups and found that the average dose of dexamethasone in the allergic group was significantly lower than that observed in the non-allergic group (P = 0.0111). Furthermore, the incidence of allergic reactions in the group that received prophylaxis of less than 12 mg of dexamethasone was significantly higher than that observed in the group that received more than 12 mg of dexamethasone (P = 0.0103). In conclusion, a lower dexamethasone dose is a possible risk factor for allergic reactions induced by the administration of oxaliplatin; however, given the retrospective design used in this study, further validation of this finding is warranted.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  allergic reaction; dexamethasone; oxaliplatin; risk factor

Mesh:

Substances:

Year:  2013        PMID: 24304429     DOI: 10.1111/ecc.12156

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  5 in total

1.  Incidence of oxaliplatin hypersensitivity reaction among colorectal cancer patients: A 5-year retrospective study.

Authors:  Sirinoot Palapinyo; Jettanong Klaewsongkram; Virote Sriuranpong; Nutthada Areepium
Journal:  Pharm Pract (Granada)       Date:  2022-03-31

2.  Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer.

Authors:  Qiuyan Song; Yuanxuan Cai; Kangyuan Guo; Min Li; Zaoqin Yu; Qirui Tai; Yuhang Zhao; Xuan Zhu; Chengliang Zhang
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

3.  Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.

Authors:  Hideki Ohta; Takahiro Hayashi; Sumie Murai; Hideyo Shiouchi; Yosuke Ando; Satomi Kumazawa; Kaori Ito; Yoshiaki Ikeda; Hiroshi Matsuoka; Kotaro Maeda; Kenji Kawada; Kimio Yasuda; Shigeki Yamada
Journal:  Cancer Chemother Pharmacol       Date:  2017-04-08       Impact factor: 3.333

4.  Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study.

Authors:  Zaoqin Yu; Rui Huang; Li Zhao; Ximin Wang; Xiaofang Shangguan; Wei Li; Min Li; Xianguo Yin; Chengliang Zhang; Dong Liu
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

Review 5.  Meta-analysis of risk factors associated with oxaliplatin hypersensitivity reactions in cancer patients.

Authors:  Linhui Zhu; Huan Li; Qiong Du; Xuan Ye; Sijia Yu; Xin Luo; Qing Zhai
Journal:  Int J Clin Oncol       Date:  2021-10-09       Impact factor: 3.402

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.